Open AccessConcise Review: Workshop Review: Understanding and Assessing the Risks of Stem Cell‐Based Therapies
Author(s) -
Heslop James A.,
Hammond Thomas G.,
Santeramo Ilaria,
Tort Piella Agnès,
Hopp Isabel,
Zhou Jing,
Baty Roua,
Graziano Enrique I.,
Proto Marco Bernabé,
Caron Alexis,
Sköld Patrik,
Andrews Peter W.,
Baxter Melissa A.,
Hay David C.,
Hamdam Junnat,
Sharpe Michaela E.,
Patel Sara,
Jones David R.,
Reinhardt Jens,
Danen Erik H.J.,
Ben-David Uri,
Stacey Glyn,
Björquist Petter,
Piner Jacqueline,
Mills John,
Rowe Cliff,
Pellegrini Giovanni,
Sethu Swaminathan,
Antoine Daniel J.,
Cross Michael J.,
Murray Patricia,
Williams Dominic P.,
Kitteringham Neil R.,
Goldring Chris E.P.,
Park B. Kevin
Publication year - 2015
Publication title -
stem cells translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.781
H-Index - 71
eISSN - 2157-6580
pISSN - 2157-6564
DOI - 10.5966/sctm.2014-0110
Subject(s) - risk analysis (engineering) , engineering ethics , identification (biology) , medicine , intensive care medicine , computer science , management science , engineering , biology , botany
Although it is important that stem cell therapies are advanced into the clinic, their safety must be continually evaluated. This review, the result of an Innovative Medicines Initiative SafeSciMET workshop with support from the UK Regenerative Medicine Platform, held at the University of Liverpool, outlines the known risks of stem cell therapeutics and discusses how they can be assessed and managed through preclinical and clinical trials to ensure the safest possible development of new products.